1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Adenoma, Oxyphilic: new trials by email Literature Review of Adenoma, Oxyphilic trials Research Report on Adenoma, Oxyphilic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Trametinib, Dabrafenib, PDR001 - Thyroid Cancer, Thyroid Cancer, Follicular | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 19 | 2020-09-02 | 2026-09-17 |
Adenocarcinoma, Follicular (1) · Thyroid Cancer, Papillary (1) · Thyroid Neoplasms (1) · Thyroid cancer, Hurthle cell (1) · Thyroid cancer, follicular (1)
Adenocarcinoma (1) · Adenocarcinoma, Papillary (1) · Adenoma (1) · Carcinoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Head and Neck Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Thyroid Diseases (1)
dabrafenib (1) · spartalizumab (1) · trametinib (1)
Memorial Sloan Kettering Cancer Center (1)
United States (1)